For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular ...

Opens in a new tab or window LOS ANGELES -- For surgeons already split on their preference of inhaled pulmonary vasodilator to prevent postoperative right ventricular (RV) failure, a shifting ...

who continue to deteriorate despite optimal pulmonary vasodilator therapy – including intravenous prostanoids and combination therapy. Identification of poor prognostic markers in PAH ...

gmail.com Objective In Fontan circulation, pulmonary arterial hypertension (PAH)-targeted therapies could improve the patients’ exercise capacity. This study aimed to investigate the effects of PAH ...

Pulmonary vasodilator treatment with the prostacyclin analogue, iloprost and the endothelin receptor antagonist, bosentan, has been reported to improve survival on the transplant waiting list and ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...

Cardiothoracic Unit, Hospital for Sick Children, London. Inhaled nitric oxide (NO) is a selective pulmonary vasodilator, potentially useful in the treatment of pulmonary hypertension and ...

HPS involves hypoxemia due to pulmonary vasodilation in cirrhotic patients, leading to significant morbidity. The pathophysiology is linked to increased levels of vasodilators and angiogenic factors.

has changed dramatically with the development of targeted therapy with selective pulmonary vasodilators. It is important to develop evidence-based guidelines for the management of these patients.

Background: Imbalance between cell proliferation and apoptosis underlies the development of pulmonary arterial hypertension (PAH). Current vasodilator treatment of PAH does not target the uncontrolled ...